PRMT5 and breast carcinoma: Similarly, in breast cancer models, tamoxifen induces nuclear translocation of the PRMT5/MEP50 methylosome complex, where it catalyzes ERα methylation and promotes the recruitment of corepressors, such as SMRT and HDAC1, leading to the suppression of ERα transcriptional activity (7).